Search the Newsreel

Gufic BioSciences consolidated net profit rises 70.70% in the June 2026 quarter

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook

Vor Biopharma (VOR) sees Frazier Life Sciences entities report under 5% ownership

Frazier Life Sciences-affiliated funds have filed an amended Schedule 13G indicating beneficial ownership of less than 5% of Vor Biopharma Inc. common stock. Frazier Life Sciences Public Fund, L.P. holds 4.2% of the class, while Frazier Life Sciences XII, L.P. holds 0.5%, and Frazier …

Why (ATRA) Price Action Is Critical for Tactical Trading

This article analyzes Atara Biotherapeutics Inc. (NASDAQ: ATRA) for tactical trading, highlighting a strong near and mid-term sentiment despite a weak long-term outlook. It identifies an exceptional 234.0:1 risk-reward setup targeting a 70.2% gain against 0.3% risk. The analysis also provides specific institutional trading …

IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough

Woodline Partners (SABS) discloses 5.46M-share beneficial stake in SAB Biotherapeutics

Woodline Partners LP has filed an amended Schedule 13G, disclosing a beneficial ownership of 5,455,355 shares, or 6.8%, of SAB Biotherapeutics, Inc. common stock. This stake includes common shares and shares issuable from Series B Preferred Stock underlying Enrollment and Data Release Warrants. The …

Skye Bioscience to acquire Redx Pharma in $125M deal By Investing.com

Skye Bioscience announced its definitive agreement to acquire Redx Pharma through a scheme of arrangement under U.K. law for an approximate $125 million deal. The merged entity will be known as Fibrx Therapeutics Inc., trading on Nasdaq, and will be led by Redx's current …

Nasdaq, S&P 500 Futures Rise Ahead Of Nvidia Earnings, Fed Minutes: Why TSLA, SLS, IBRX, CAVA, POET, BA Are In Focus

BioRestorative Therapies suspends shipments of ExoCR and BioX products for review

BioRestorative Therapies (NASDAQ:BRTX) has suspended all orders and shipments of its ExoCR and BioX biocosmeceutical product lines, effective August 7, pending a business review and regulatory assessment. The company, which has a market cap of $5.61 million and generated only $360,000 in revenue in …

Theravance Biopharma (TBPH): Newtyn discloses 6.7% holdings in amended 13G/A

Newtyn Management, LLC has disclosed a 6.7% beneficial ownership in Theravance Biopharma (TBPH) through an amended Schedule 13G filing. While Newtyn TE Partners, LP, a part of Newtyn Management, has reduced its holdings to below the 5% reporting threshold, Newtyn Management itself remains above …

Form 8K BioRestorative Therapies Inc For: 14 August By Investing.com

This article reports that BioRestorative Therapies Inc. filed a Form 8K on August 14th. The filing is brief and primarily serves as an announcement of this corporate action.

Krystal Biotech(KRYS.US) Director Sells US$8.23 Million in Common Stock

Krystal Biotech (KRYS.US) Director, Daniel Meyer, sold 84,200 shares of common stock on August 13, 2026, for a total of $8.23 million. The shares were sold at an average price of $97.75. Following this transaction, Meyer directly owns 10,000 shares of the company.

Swedish Orphan Biovitrum (OM:SOBI) Following Its Lacutamab Deal And The Undervalued Narrative

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Swedish Orphan Biovitrum Stock Is Back In Focus Swedish Orphan Biovitrum (OM:SOBI) has drawn fresh attention after a new partnership with Innate Pharma …

Orchestra BioMed (OBIO) director uses 5,145 shares to cover RSU tax withholding

Orchestra BioMed Holdings, Inc. director Eric S. Fain reported an indirect disposition of 5,145 common stock shares on August 12, 2026. These shares were withheld by the company to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) and no …

TuHURA Biosciences Expect Preliminary Results From IR Study IFX-2.0 With Keytruda for Deep Seated MCC in 1H2027 >HURA

TuHURA Biosciences anticipates preliminary results from its IFX-2.0 study, which combines IFX-2.0 with Keytruda for treating deep-seated Merkel Cell Carcinoma (MCC). These results are expected in the first half of 2027. This study represents a key milestone for TuHURA Biosciences in its development of …

Ikarian Capital (CNTB) discloses 6.9% Connect Biopharma holding on Schedule 13G/A

Ikarian Capital, LLC and Neil Shahrestani have disclosed a 6.9% beneficial ownership in Connect Biopharma Holdings Limited Ordinary Shares through a Schedule 13G/A filing. This ownership amounts to 4,338,534 shares, based on 62,974,309 Ordinary Shares outstanding as of July 31, 2026. The filing indicates …

Boundless Bio (BOLD): ADAR1 Capital discloses 8.8% beneficial ownership stake

ADAR1 Capital Management, LLC has disclosed an 8.8% beneficial ownership stake in Boundless Bio, Inc. (BOLD), totaling 1,968,216 shares. This stake, based on 22,475,000 shares outstanding as of June 30, 2026, is subject to shared voting and dispositive power by ADAR1 Capital Management and …

Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells 18,258 Shares

Cue Biopharma CEO Shao-Lee Lin sold 18,258 shares of the company's stock for over $522,000 to cover tax withholding obligations from vested equity awards. This sale reduced her ownership by 2.52%, following a previous sale of 40,000 shares for $1.08 million. The company recently …

Cue Biopharma CEO Lin sells shares worth $1.6 million

Cue Biopharma CEO Lin Shao-Lee sold shares worth $1.6 million, primarily to cover tax obligations from vested restricted stock units, not as discretionary sales. Concurrently, Mr. Lin acquired 109,179 shares from vested performance stock units. The company has also appointed a new Chief Medical …

Insider plans 58,258-share stock sale (NASDAQ: CUE) under Rule 144

An insider of Cue Biopharma (NASDAQ: CUE) has filed a Rule 144 notice to sell up to 58,258 shares of common stock. These shares originated from restricted stock units that vested on August 1, 2026. The sale is planned to occur in two tranches …

Bright Minds Biosciences (NASDAQ:DRUG) Issues Quarterly Earnings Results

Bright Minds Biosciences (NASDAQ:DRUG) reported quarterly earnings per share of ($0.17), significantly surpassing analysts' consensus estimate of ($1.28). Following the announcement, shares fell 2.0% to $76.44. Analysts maintain a generally positive outlook on the stock, with an average "Buy" rating and a consensus price …

Moleculin Biotech Releases Q2 2026 Financial Results

Moleculin Biotech (MBRX) reported a net loss of $7.6 million for Q2 2026, with a significant improvement in loss per share, narrowing to $1.40 from $12.25 in Q2 2025. The company, focused on therapeutic candidates for tumors and viruses, generated no revenue but continued …

Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Estimates By $22.45 EPS

Is Castle Biosciences Inc (CSTL) a Bargain After 3.0% Drop? GF Value Says Undervalued

Castle Biosciences Inc (CSTL) shares recently dropped 3.0%, leading to a 7.5% decrease over the past week, but GuruFocus' GF Value indicates the stock is slightly undervalued. Despite a strong GF Score of 81/100, driven by high growth potential, the company faces significant challenges …

Discipline and Rules-Based Execution in BCRX Response

This article provides an AI-driven analysis for Biocryst Pharmaceuticals Inc. (BCRX), highlighting strong sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 15.0% gain. It details three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for …

Wuxi Biologics (Cayman) Stock Sheds 1.3% in Hong Kong

Perceptive Advisors (NASDAQ: SLDB) details 11.2% beneficial stake and warrant limits

Perceptive Advisors LLC and related entities, including Joseph Edelman, have reported a beneficial ownership of 12,046,579 shares in Solid Biosciences Inc. (NASDAQ: SLDB), representing an 11.2% stake. This includes common stock and pre-funded warrants, with the latter subject to a 9.99% beneficial ownership limitation …

TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS

Valion Bio (VBIO) investor group reports 1.74M shares, capped at 9.9% stake

An investor group comprising 3i, LP, Tumim Stone Capital, LLC, 3i Management LLC, and Maier J. Tarlow has filed an amended Schedule 13D for Valion Bio, Inc. (VBIO), reporting beneficial ownership of 1,742,699 common shares, representing a 9.9% stake. This percentage is calculated based …

Athira Pharma (NASDAQ:LONA) Announces Quarterly Earnings Results

Athira Pharma (NASDAQ:LONA) reported quarterly earnings of ($0.80) per share, significantly beating the consensus estimate of ($1.90). Following the announcement, shares rose 1.4% to $7.98. Analysts maintain a "Moderate Buy" rating with a $16 price target, and institutional investors hold 57.12% of the company's …

CSTL (CSTL) files notice to sell 24,908 common shares on NASDAQ

A holder of CSTL common stock has filed a notice of intent to sell up to 24,908 shares on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services. The indicated aggregate market value of these shares is $741,493.72, and they originated from restricted …

Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?

Biohaven Ltd. reported narrowing losses in Q2 2026, with a net loss of US$137.31 million, and appointed AI-focused investor John Yetimoglu to its Board. Despite these developments, the company still faces significant financial risk due to zero revenue, heavy ongoing losses, and a short …

Dino Rossi Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will …

BioXcel Therapeutics (BTAI) files Form 3 for new director Susan E. Atkins

BioXcel Therapeutics, Inc. (BTAI) has filed a Form 3 to report the initial beneficial ownership for its new director, Susan E. Atkins. This filing indicates her position as a director but does not list any equity transactions or current holdings. The document also notes …

BioXcel Therapeutics (BTAI) director receives option grant for 17,000 shares

BioXcel Therapeutics director Susan E. Atkins was granted stock options for 17,000 shares of common stock on August 12, 2026, with an exercise price of $1.06 per share and an expiration date of August 12, 2036. The options will vest over three years, with …